Novel Medication as a Potential Smoking Cessation Aid

University of Minnesota56 enrolled

Overview

The purpose of this study is to provide preliminary information assessing if levomilnacipran may be effective at increasing smoking cessation rates.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

TRIPLE

Enrollment

Conditions

Tobacco Use Disorder

Interventions

LevomilnacipranDRUG

PlaceboDRUG

Eligibility

Sex: ALLMin age: 25 YearsMax age: 55 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Be between 25 years old and 55 years old * Smoke a minimum number of cigarettes per day * Indicate motivation to quit smoking Exclusion Criteria: * Current or history of medical or psychiatric conditions that could interfere with measures being studied or that could be affected by the study medication * Use of medication that could interfere with measures to be studied or that could be expected to interact with levomilnacipran * Are pregnant or breast feeding The investigators will evaluate if there are other reasons why someone may not be eligible to participate

Locations (1)

Clinical and Translational Sciences Institute

Minneapolis, Minnesota, United States

Outcomes

Primary Outcomes

Percent of Days of Confirmed Abstinence (Out of 5 Maximum)

Subjects will be asked to abstain for five consecutive days during the third week of each intervention period with the percentage of confirmed abstinence days being the primary outcome measure

Time frame: 5 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.